Botulinum toxin treatment of secretory disorders
Identifieur interne : 005A63 ( Main/Merge ); précédent : 005A62; suivant : 005A64Botulinum toxin treatment of secretory disorders
Auteurs : Markus Naumann [Allemagne] ; Wolfgang Jost [Allemagne]Source :
- Movement disorders [ 0885-3185 ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002237
- to stream PascalFrancis, to step Curation: 000A84
- to stream PascalFrancis, to step Checkpoint: 002225
Links to Exploration step
Pascal:04-0228841Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Botulinum toxin treatment of secretory disorders</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Basse-Franconie</region>
<settlement type="city">Wurtzbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Wiesbaden</wicri:noRegion>
<wicri:noRegion>Deutsche Klinik für Diagnostik</wicri:noRegion>
<wicri:noRegion>Wiesbaden</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0228841</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0228841 INIST</idno>
<idno type="RBID">Pascal:04-0228841</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002237</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A84</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002225</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Naumann M:botulinum:toxin:treatment</idno>
<idno type="wicri:Area/Main/Merge">005A63</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Botulinum toxin treatment of secretory disorders</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Basse-Franconie</region>
<settlement type="city">Wurtzbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Wiesbaden</wicri:noRegion>
<wicri:noRegion>Deutsche Klinik für Diagnostik</wicri:noRegion>
<wicri:noRegion>Wiesbaden</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Bontoxilysin</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Bavière</li>
<li>District de Basse-Franconie</li>
</region>
<settlement><li>Wurtzbourg</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Bavière"><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
</region>
<name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005A63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005A63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= Pascal:04-0228841 |texte= Botulinum toxin treatment of secretory disorders }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |